Apellis Pharmaceuticals (APLS) Competitors

$41.03 0.00 (0.00%)

As of 05/14/2026 03:30 PM Eastern

APLS vs. ROIV, VTRS, GMAB, ASND, and RGC

Should you buy Apellis Pharmaceuticals stock or one of its competitors? MarketBeat compares Apellis Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apellis Pharmaceuticals include Roivant Sciences (ROIV), Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry.

How does Apellis Pharmaceuticals compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Roivant Sciences has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Apellis Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Apellis Pharmaceuticals has a net margin of 12.06% compared to Roivant Sciences' net margin of -6,079.94%. Apellis Pharmaceuticals' return on equity of 39.71% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-6,079.94%	-19.04%	-18.15%
Apellis Pharmaceuticals	12.06%	39.71%	13.20%

Apellis Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$29.05M	721.61	-$171.98M	-$1.17	N/A
Apellis Pharmaceuticals	$1.00B	5.23	$22.39M	$1.02	40.23

In the previous week, Apellis Pharmaceuticals had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 6 mentions for Apellis Pharmaceuticals and 5 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.56 beat Apellis Pharmaceuticals' score of 0.52 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apellis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences presently has a consensus target price of $30.55, suggesting a potential upside of 4.30%. Apellis Pharmaceuticals has a consensus target price of $35.72, suggesting a potential downside of 12.94%. Given Roivant Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Roivant Sciences is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09

Summary

Apellis Pharmaceuticals beats Roivant Sciences on 9 of the 16 factors compared between the two stocks.

How does Apellis Pharmaceuticals compare to Viatris?

Apellis Pharmaceuticals (NASDAQ:APLS) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Apellis Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market. Comparatively, Viatris has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Apellis Pharmaceuticals currently has a consensus price target of $35.72, suggesting a potential downside of 12.94%. Viatris has a consensus price target of $15.71, suggesting a potential downside of 4.65%. Given Viatris' stronger consensus rating and higher probable upside, analysts clearly believe Viatris is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Apellis Pharmaceuticals has a net margin of 12.06% compared to Viatris' net margin of -2.04%. Apellis Pharmaceuticals' return on equity of 39.71% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apellis Pharmaceuticals	12.06%	39.71%	13.20%
Viatris	-2.04%	19.04%	7.62%

96.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Viatris had 3 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 9 mentions for Viatris and 6 mentions for Apellis Pharmaceuticals. Viatris' average media sentiment score of 0.73 beat Apellis Pharmaceuticals' score of 0.52 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apellis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Apellis Pharmaceuticals has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apellis Pharmaceuticals	$1.00B	5.23	$22.39M	$1.02	40.23
Viatris	$14.30B	1.34	-$3.51B	-$0.26	N/A

Summary

Apellis Pharmaceuticals beats Viatris on 9 of the 16 factors compared between the two stocks.

How does Apellis Pharmaceuticals compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genmab A/S presently has a consensus target price of $39.07, suggesting a potential upside of 47.22%. Apellis Pharmaceuticals has a consensus target price of $35.72, suggesting a potential downside of 12.94%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities analysts plainly believe Genmab A/S is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09

Genmab A/S has a net margin of 21.05% compared to Apellis Pharmaceuticals' net margin of 12.06%. Apellis Pharmaceuticals' return on equity of 39.71% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Apellis Pharmaceuticals	12.06%	39.71%	13.20%

Genmab A/S has higher revenue and earnings than Apellis Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.45	$963M	$1.32	20.11
Apellis Pharmaceuticals	$1.00B	5.23	$22.39M	$1.02	40.23

Genmab A/S has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Apellis Pharmaceuticals has a beta of -0.24, meaning that its stock price is 124% less volatile than the broader market.

In the previous week, Genmab A/S and Genmab A/S both had 6 articles in the media. Genmab A/S's average media sentiment score of 0.60 beat Apellis Pharmaceuticals' score of 0.52 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apellis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Apellis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Apellis Pharmaceuticals compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Apellis Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

Ascendis Pharma A/S has a net margin of 57.87% compared to Apellis Pharmaceuticals' net margin of 12.06%. Apellis Pharmaceuticals' return on equity of 39.71% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Apellis Pharmaceuticals	12.06%	39.71%	13.20%

In the previous week, Ascendis Pharma A/S had 1 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 6 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.52 beat Ascendis Pharma A/S's score of 0.47 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apellis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apellis Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$865.78M	17.33	-$258M	$8.67	27.74
Apellis Pharmaceuticals	$1.00B	5.23	$22.39M	$1.02	40.23

Ascendis Pharma A/S presently has a consensus target price of $291.78, suggesting a potential upside of 21.32%. Apellis Pharmaceuticals has a consensus target price of $35.72, suggesting a potential downside of 12.94%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.95
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09

Summary

Ascendis Pharma A/S beats Apellis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Apellis Pharmaceuticals compare to Regencell Bioscience?

Apellis Pharmaceuticals (NASDAQ:APLS) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Apellis Pharmaceuticals presently has a consensus target price of $35.72, indicating a potential downside of 12.94%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Apellis Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apellis Pharmaceuticals has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market.

Apellis Pharmaceuticals has a net margin of 12.06% compared to Regencell Bioscience's net margin of 0.00%. Apellis Pharmaceuticals' return on equity of 39.71% beat Regencell Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apellis Pharmaceuticals	12.06%	39.71%	13.20%
Regencell Bioscience	N/A	N/A	N/A

In the previous week, Regencell Bioscience had 15 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 21 mentions for Regencell Bioscience and 6 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.52 beat Regencell Bioscience's score of 0.08 indicating that Apellis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apellis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Apellis Pharmaceuticals has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apellis Pharmaceuticals	$1.00B	5.23	$22.39M	$1.02	40.23
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 6.5% of Apellis Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Apellis Pharmaceuticals beats Regencell Bioscience on 11 of the 13 factors compared between the two stocks.

Get Apellis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLS vs. The Competition

Export

Metric	Apellis Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.25B	$3.31B	$6.38B	$12.30B
Dividend Yield	N/A	2.35%	2.81%	5.27%
P/E Ratio	40.23	18.50	20.66	25.27
Price / Sales	5.23	284.70	551.98	75.61
Price / Cash	196.33	121.77	42.43	54.86
Price / Book	12.66	6.63	9.87	6.90
Net Income	$22.39M	$24.40M	$3.57B	$334.66M
7 Day Performance	0.00%	4.14%	0.23%	0.12%
1 Month Performance	0.32%	-4.80%	-2.54%	-0.18%
1 Year Performance	135.13%	62.87%	33.54%	30.62%

Apellis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLS Apellis Pharmaceuticals	1.6872 of 5 stars	$41.03 flat	$35.72 -12.9%	+135.1%	$5.25B	$1.00B	40.23	770	Analyst Forecast High Trading Volume
ROIV Roivant Sciences	2.174 of 5 stars	$28.96 +1.4%	$30.55 +5.5%	+171.5%	$20.44B	$29.05M	N/A	860	Upcoming Earnings
VTRS Viatris	2.7383 of 5 stars	$16.92 -1.5%	$15.71 -7.1%	+86.4%	$20.00B	$14.30B	N/A	30,000	Gap Down
GMAB Genmab A/S	4.2608 of 5 stars	$26.18 -0.9%	$39.07 +49.2%	+33.5%	$16.48B	$3.90B	19.83	3,029
ASND Ascendis Pharma A/S	3.7026 of 5 stars	$238.67 +0.0%	$291.50 +22.1%	+52.6%	$14.89B	$814.57M	27.53	1,189	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLS) was last updated on 5/17/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apellis Pharmaceuticals (APLS) Competitors

APLS vs. ROIV, VTRS, GMAB, ASND, and RGC

How does Apellis Pharmaceuticals compare to Roivant Sciences?

Summary

How does Apellis Pharmaceuticals compare to Viatris?

Summary

How does Apellis Pharmaceuticals compare to Genmab A/S?

Summary

How does Apellis Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Apellis Pharmaceuticals compare to Regencell Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLS vs. The Competition

Apellis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apellis Pharmaceuticals (APLS) Competitors

APLS vs. ROIV, VTRS, GMAB, ASND, and RGC

How does Apellis Pharmaceuticals compare to Roivant Sciences?

Which has more risk and volatility, ROIV or APLS?

Do institutionals & insiders hold more shares of ROIV or APLS?

Is ROIV or APLS more profitable?

Which has preferable earnings and valuation, ROIV or APLS?

Does the media refer more to ROIV or APLS?

Do analysts prefer ROIV or APLS?

Summary

How does Apellis Pharmaceuticals compare to Viatris?

Which has more volatility & risk, APLS or VTRS?

Do analysts prefer APLS or VTRS?

Is APLS or VTRS more profitable?

Do insiders and institutionals hold more shares of APLS or VTRS?

Does the media refer more to APLS or VTRS?

Which has better earnings & valuation, APLS or VTRS?

Summary

How does Apellis Pharmaceuticals compare to Genmab A/S?

Do institutionals and insiders have more ownership in GMAB or APLS?

Do analysts recommend GMAB or APLS?

Is GMAB or APLS more profitable?

Which has preferable earnings and valuation, GMAB or APLS?

Which has more volatility & risk, GMAB or APLS?

Does the media prefer GMAB or APLS?

Summary

How does Apellis Pharmaceuticals compare to Ascendis Pharma A/S?

Do institutionals & insiders have more ownership in ASND or APLS?

Which has more risk and volatility, ASND or APLS?

Is ASND or APLS more profitable?

Does the media favor ASND or APLS?

Which has stronger valuation and earnings, ASND or APLS?

Do analysts recommend ASND or APLS?

Summary

How does Apellis Pharmaceuticals compare to Regencell Bioscience?

Do analysts prefer APLS or RGC?

Which has more risk & volatility, APLS or RGC?

Is APLS or RGC more profitable?

Does the media prefer APLS or RGC?

Which has preferable valuation and earnings, APLS or RGC?

Do institutionals and insiders have more ownership in APLS or RGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLS vs. The Competition

Apellis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools